Medicine

Molecular profiling of BRAF-V600E-mutant metastatic colorectal cancer cells in the phase\u00e2 $ 3 LIGHTHOUSE CRC test

.Completing passions.S.K.: Stock as well as Various Other Ownership Rate Of Interests: Iylon, Lutris, MolecularMatch, Navire. Consulting or Advisory Function: AbbVie, Amal Therapies, AstraZeneca/MedImmune, Bayer Health, Bicara Therapeutics, Boehringer Ingelheim, Boston Ma Biomedical, Carina Biotech, Daiichi Sankyo, EMD Serono, Undertaking BioMedicines, Blaze Biosciences, Genentech, Gilead Sciences, GSK, HalioDx, Holy Rock Medical Care, Inivata, Ipsen, Iylon, Jacobio, Jazz Music Pharmaceuticals, Lilly, Lutris, Merck, Mirati Therapies, Natera, Novartis, Numab, Pfizer, Pierre Fabre, Redx Pharma, Repare Therapy, Servier, Xilis. Research Study Financing: Amgen (Inst), Array BioPharma (Inst), Biocartis (Inst), Daiichi Sankyo (Inst), EMD Serono (Inst), Genentech/Roche (Inst), Guardant Wellness (Inst), Lilly (Inst), MedImmune (Inst), Novartis (Inst), Sanofi (Inst). D.A.M.: Work: Previously Pfizer. Sell and Other Possession Interests: Pfizer. J.P.: Job: In The Past Pfizer. Sell as well as Various Other Possession Stakes: Pfizer. F.C.: Consulting or even Advisory Task: Amgen, Bayer, Merck KGaA, Pfizer, Roche/Genentech. Research Funding: Amgen (Inst), Bayer (Inst), Bristol Myers Squibb (Inst), Ipsen (Inst), Merck KGaA (Inst), MSD (Inst), Roche/Genentech (Inst), Servier (Inst), Symphogen (Inst). J.D.: Consulting or Advisory Task: Amgen (Inst), Bayer, BeiGene, Daiichi Sankyo, Eisai, GSK, Merck KGaA, Pierre Fabre. Study Funding: AstraZeneca/MedImmune (Inst), BeiGene (Inst), Bionomics (Inst), Bristol Myers Squibb (Inst), GSK (Inst), Lilly (Inst), Novartis (Inst), Roche (Inst). E.V.C.: Consulting or even Advisory Role: AbbVie, Agenus, ALX, Amgen, Arcus Biosciences, Astellas Pharma, AstraZeneca, Bayer, BeiGene, BioNTech, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, Debiopharm, ElmediX, Eisai, GSK, Hookipa Biotech, Incyte, Ipsen, Lilly, Merck Sharp &amp Dohme, Merck KGaA, Mirati, Novartis, Nordic, Pierre Fabre, Pfizer, Roche, Seagen, Servier, Simcere, Takeda, Taiho Pharmaceutical, Terumo. H.S.W.: Consulting or Advisory Function: Amgen, Bayer, Bristol Myers Squibb (Celgene), Boehringer Ingelheim (DMC), BTG, EXACT Therapeutics, Erytech Pharma, Incyte, Merck KGaA, Oaktree Life Sciences, OncoSil, Pfizer, Pierre Fabre, Roche/Genentech, Seagen, Servier, County, Sirtex Medical, Takeda (Hutchinson Med), Zymeworks. Analysis Backing: Merck KGaA (Inst), MSD (Inst), Pfizer (Inst), Sirtex Medical (Inst). T.Y.: Honoraria: Bayer Yakuhin, Chugai Pharma, Merck KGaA, MSD, Ono Pharmaceutical, Sumitomo Corp., Takeda. Investigation Backing: Amgen (Inst), Boehringer Ingelheim (Inst), Chugai Pharma (Inst), Daiichi Sankyo Co., Ltd. (Inst), Eisai, FALCO Biosystems, Genomedia (Inst), Molecular Health And Wellness, MSD (Inst), Nippon Boehringer Ingelheim, Ono Pharmaceutical (Inst), Pfizer (Inst), Roche Diagnostics, Sanofi (Inst), Sumitomo Dainippon (Inst), Sysmex (Inst), Taiho Drug (Inst). H.S.: Work: Pfizer. Inventory and also Various Other Ownership Interests: Pfizer. X.Z.: Job: Pfizer. Assets and also Other Possession Stakes: Pfizer. Patents, Aristocracies, Other Patent: Johns Hopkins University. P.H.: Employment: Pfizer. Supply as well as Various Other Possession Stakes: Pfizer. T.X.: Job: Pfizer. Stock as well as Other Possession Stakes: Pfizer. R.Y.: Consulting or Advisory Duty: Assortment BioPharma/Pfizer, Mirati Therapeutics, Zai Laboratory, Amgen. Research Funding: Collection BioPharma (Inst), Boehringer Ingelheim (Inst), Mirati Therapeutics (Inst), Pfizer (Inst), Daiichi Sankyo (Inst). J.T.: Consulting or even Advisory Task: Assortment BioPharma, AstraZeneca, Bayer, Boehringer Ingelheim, Chugai Pharma, Daiichi Sankyo, F. Hoffmann-La Roche, Genentech, HalioDx, Hutchison MediPharma, Ikena Oncology, Inspirna Inc., IQVIA, Lilly, Menarini, Merck Serono, Merus, Mirati Therapeutics, MSD, NeoPhore, Novartis, Ona Therapeutics, Orion Biotechnology, Peptomyc, Pfizer, Pierre Fabre, Samsung Bioepis, Sanofi, Scandion Oncology, Scorpion Rehab, Seagen Inc., Servier, Taiho Drug, Tessa Therapeutics, TheraMyc. Other Relationship: Amgen, Selection Biopharma, BeiGene, Boehringer Ingelheim, BMS, Cancer Cells Research Study UK, Celgene, Debiopharm, F. Hoffman-La Roche, Fundaciu00c3 u00b3 n Cientu00c3fica de la Asociaciu00c3 u00b3 n Espau00c3 u00b1 ola Opposite el Cu00c3 u00a1 ncer, Genentech, HalioDX, Hutchinson Medipharma, Imedex, Janssen-Cilag, MedImmune, Medscape, Menarini, Merck Health KGaA, MJH Lifestyle Sciences, MSD, Merus, Mirati, Novartis, Oniria Therapies, PeerView Principle for Medical Education And Learning, Pfizer, PharmaMar, Physicansu00e2 $ Learning Information, Sanofi-Aventis, Servier, Taiho Pharmaceutical.